Top News

• PENG stock soared more than 25% at close on Tuesday after analysts increased price targets on the company, citing benefits from continued AI demand.
• ANET stock surged nearly 9% at close amid growing optimism for its cloud networking and data center solutions.
• BCRX closed up 1% amid growing takeover buzz following Vertex Pharmaceuticals’ acquisition of Crinetics.

Shares of Penguin Solutions Inc. (PENG), Arista Networks Inc. (ANET), and Biocryst Pharmaceuticals Inc. (BCRX) surged to 52-week highs on Wednesday amid a series of positive catalysts and Wall Street price target hikes.

Add Asianet Newsable as a Preferred Source

PENG stock soared more than 25% at close on Tuesday after analysts increased price targets on the company, citing benefits from continued AI demand.

ANET stock surged nearly 9% at close amid growing optimism for its cloud networking and data center solutions, while BCRX closed up 1% amid a growing takeover buzz.

Penguin Benefits From Wall Street Optimism

PENG stock climbed to an annual high of $80 as Wall Street upped its price target on the company, citing continued demand for its AI infrastructure and memory products.

Citizens upped the price target on Penguin Solutions to $85 from $65 and kept an ‘Outperform’ rating on the shares. The revised target still represents about an 8% upside from the stock’s last closing price.

The analyst noted that as the company forges ahead with AI-driven product innovation and pivots from non-core assets, its financial profile is likely to get stronger with respect to growth and an improving business mix.

Rosenblatt analyst Sajal Dogra also raised the price target on the company to $80 from $75 and maintained a ‘Buy’ rating on the shares. The analyst said that it continues to like Penguin as enterprises increasingly adopt agentic AI workloads powered by inference at scale. Stifel and Needham also increased their price targets on Penguin Solutions.

PENG stock is up more than 286% this year, while retail sentiment on Stocktwits was in the ‘extremely bullish’ territory at the time of writing.

Arista Networks Gains On Soaring Demand

ANET stock is surging as it benefits from growing demand for AI infrastructure, with hyperscalers and cloud providers expanding data center capacity to support increasingly complex AI workloads. The stock hit a fresh 52-week high of $181.27 on Wednesday.

Earlier in June, the company launched its 7060XE7 Series, a new portfolio of 1.6T networking platforms designed for rack-scale AI infrastructure that requires high-performance Ethernet connectivity.

ANET also received a boost from its inclusion in the Russell Top 50 Index in late June, which increased optimism about the company’s strong position in the AI ecosystem.

Wall Street analysts have also upped their targets on the company in late June, with KeyBanc analyst Brandon Nispel hiking the price target on Arista Networks to $200 from $178 and maintaining an ‘Overweight’ rating on the shares following meetings with the company that confirmed "exceptional demand," a key catalyst coming from XPU, and an additional catalyst coming from Inference, as per TheFly.

Morgan Stanley, Bank of America, and Raymond James also hiked their targets on the company. Thirty analysts have a 12-month average price target of $190.09 for the company, according to Koyfin data. This implies an upside of about 5% from its last close.

ANET stock is up 35.52% this year, while retail sentiment on Stocktwits was in the ‘extremely bullish’ territory at the time of writing.

Biocryst Pharmaceuticals Gains On Potential Takeover Speculations

BCRX stock surged to a new annual high of $11.19 on Wednesday as it gained from market rotation into biotech stocks that are viewed as potential winners from an ongoing mergers and acquisitions cycle.

The buzz followed Crinetics’ acquisition by Vertex Pharmaceuticals in a deal worth roughly $10 billion. The offer, which more than doubled Crinetics' previous closing price, expands Vertex's presence in rare endocrine disorders and signals that large pharmaceutical companies remain willing to pay substantial premiums for high-quality biotech assets.

Wall Street is also increasingly optimistic about the stock, with its average 12-month target of $21.90 implying an upside of about 97% from its last close. Of the 10 analysts covering the stock, all rate it 'Buy' or higher, with no 'Hold,' 'Sell' or 'Strong Sell' ratings.

Shares of the company have surged about 48% so far this year, with retail sentiment in the ‘extremely bullish’ territory at the time of writing.

For updates and corrections, email newsroom[at]stocktwits[dot]com.<